Co-delivery nanocarriers, combining chemotherapeutics with resistance-modulating agents (e.g., siRNAs targeting MDR1 or PI3K inhibitors), target multiple resistance pathways, improving outcomes in resistant BC [285]. This evidence concerns the gene ABCB1 and breast cancer.